|
|
4350 Executive Drive, Suite 325
San Diego, CA 92121 USA
phone:(858) 452-2323
fax:(858) 452-1222
|
|
| Symbol |
CYPB |
| Exchange |
Nasdaq |
| Founded |
0 |
| Employees |
10 |
|
|
| www.cypressbio.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Biotechnology treatment for Functional Somatic Syndromes. |
|
| Management |
| Jay D. Kranzler, M.D., Ph.D., Chief Executive Officer and Chairman of the Board; Sabrina Martucci Johnson, Executive Vice President, Chief Operating Officer and Chief Financial Officer; R. Michael Gendreau, M.D., Ph.D., Vice President Clinical Development, Chief Medical Officer; Srinivas G. Rao, M.D., Ph.D., Chief Scientific Officer |
| |
|
|
|
|
|
|
|
| Keywords |
| medicine, physicians, pain, rheumatology, rehabilitation |
|
|
|
| Description |
|
Cypress Bioscience, Inc. is committed to being the innovator and commercial leader in providing products for the diagnosis and treatment of chronic pain and central nervous system (CNS) disorders such as Functional Somatic Syndromes (FSSs), Fibromyalgia Syndrome (FMS) and other related disorders. The group develops a novel therapeutic agent for the treatment of blood platelet disorders. Their first product treats defective immune systems so that it can more effectively respond to certain diseases. |
|
| Products / Services |
Milnacipran is suited for development to treat FMS. Increasing evidence suggests that the pain in FMS is centrally mediated, and the modulation of more than one neurotransmittr system is likely to be required for optimal efficacy in treating the pain associated with this condition. Milnacipran, the first of a new class of agents known as NSRI's, or Nonepineprhine Serotonin Reuptake Inhibitors, acts on the two key neurotransmitters in the human body which are involved with the central modulation of chronic pain.
|
|
| Market / Customers |
The annual costs associated with Fibromyalgia Syndrome (FMS) are estimated to total billions of dollars. Over 70% of the U.S. population will at some point suffer from an FSS. Somatic complaints account for 50-60% of office visits in the primary care setting. FMS is estimated to affect between 2 to 4% of the population, and is the second most commonly diagnosed rheumatological disorder after osteoarthritis. The symptoms of FMS are chronic and widespread pain and stiffness throughout the body accompanied by severe fatigue, poor sleep and headache. There is also a high incidence of associated neurologic, allergic, cardiac, pulmonary, gastrointestinal, genitourinary, and affective symptoms among sufferers. Patients with FMS have at least comparable disability, more pain, and lower quality of life than patients with rheumatoid arthritis or osteoarthritis.
|
|
| Competitors / Substitutes / Alternatives |
Corixa Corporation, Immunex Corporation, Amgen Inc (AMGN), La Jolla Pharmaceutical Co (LJPC)
|
|
| Strategy |
Their business strategy combines novel technology with clinical development of well-characterized drugs that they believe will offer strong potential to treat Functional Somatic Syndromes (FSSs). Underlying the company's unique multidisciplinary approach to developing drugs to treat FFSs, they have formed cross-functional advisory boards to include distinguished and internationally renowned physicians and clinicians, who chair scientific committees of major investigators and designers of pharmaceutical company clinical trials that led to drugs that are currently marketed.
|
|
| Funding |
| Cypress Bioscience is interested in garnering investor funds to gain exposure and further their research. The ultimate goals of such initiatives include increasing Cypress' exposure through scientific publications, preparing and supporting patent applications, finding novel agents and pharmacology with likely efficacy in FMS, and supporting milnacipran marketing by differentiating this agent from others on the market. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
